Peptide Reference Library

BPC-157 is a synthetic peptide consisting of 15 amino acids, derived from a partial sequence of a protein found in human gastric juice. It has been studied in animal models in the context of tissue repair, tendon and ligament healing, and gastrointestinal protection. Preclinical research has explored its potential interactions with nitric oxide and growth factor pathways. It is frequently discussed in biohacking and longevity communities.

Ranges sourced from community forums and published preclinical literature. Not dosing guidance.

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring peptide present in most human and animal cells. It has been studied in animal models in the context of wound healing, tissue repair, and inflammatory response modulation. Preclinical research has explored its interactions with actin regulation and cell migration. It is widely discussed in biohacking communities focused on recovery.

Ranges sourced from community forums and published preclinical literature. Not dosing guidance.

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It has been studied in the context of growth hormone secretion and is available in two forms: with Drug Affinity Complex (DAC) for extended duration, and without DAC (also called Modified GRF 1-29) for shorter activity. It is discussed in communities focused on growth hormone optimization, body composition, and recovery.

Ranges sourced from community forums and published preclinical literature. Not dosing guidance.

Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue. It has been studied in human and animal models in the context of growth hormone release with minimal reported effect on cortisol or prolactin levels, distinguishing it from earlier secretagogues. It is discussed in communities focused on growth hormone optimization, sleep quality, and body composition.

Ranges sourced from community forums and published preclinical literature. Not dosing guidance.

GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It has been studied in both human and animal models in the context of wound healing, skin remodeling, and collagen synthesis. Dermatological research has explored its role in skin repair and hair follicle function. It is discussed in communities focused on skin health, anti-aging, and tissue repair.

Ranges sourced from community forums and published preclinical literature. Not dosing guidance.

A synthetic 29-amino-acid peptide corresponding to the first 29 residues of endogenous growth hormone-releasing hormone (GHRH), retaining full biological activity at the GHRH receptor. Sermorelin was studied in clinical trials and received FDA approval in the 1990s for diagnosis and treatment of pediatric idiopathic growth hormone deficiency (marketed as Geref), but was voluntarily discontinued in 2008 for commercial reasons unrelated to safety or efficacy. It is one of the most frequently discussed GHRH analogues in anti-aging and optimization communities in the context of pulsatile GH stimulation, body composition, and sleep quality.

Ranges sourced from FDA prescribing information (Geref), published clinical literature, and community forums. Not dosing guidance.

A synthetic 44-amino-acid modified GHRH analogue with a trans-3-hexenoic acid group at the N-terminus conferring enhanced resistance to DPP-IV enzymatic degradation. Tesamorelin is FDA-approved (as Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, making it the only GH secretagogue with an active FDA-approved indication. It has been studied in Phase 3 randomized controlled trials demonstrating selective reduction of visceral adipose tissue and is discussed in optimization communities in the context of body composition, metabolic health, and anti-aging protocols.

Ranges sourced from FDA prescribing information (Egrifta labels), published Phase 3 clinical trial data, and community forums. Not dosing guidance.

A non-peptide, orally active small molecule that acts as a potent agonist of the growth hormone secretagogue receptor (GHS-R1a), mimicking endogenous ghrelin to stimulate pulsatile GH and IGF-1 release. MK-677 has been studied in multiple human randomized controlled trials across indications including sarcopenia, diet-induced catabolism, Alzheimer's disease, hip fracture recovery, and sleep quality, but has not received FDA approval for any indication. It is discussed in biohacking communities in the context of GH optimization, body composition, sleep improvement, and recovery, and is notable for its oral bioavailability and ~24-hour effective half-life.

Ranges sourced from published clinical trial protocols, community forums, and peptide education sites. Not dosing guidance.

A synthetic hexapeptide growth hormone-releasing peptide (GHRP) that acts as a potent agonist of the GHS-R1a receptor. Hexarelin has been studied in Phase II human clinical trials for GH-releasing activity across multiple dose-response studies and is discussed in the research literature for its unique dual-receptor pharmacology — binding both GHS-R1a and the CD36 scavenger receptor, mediating GH-independent cardioprotective effects. It is discussed in biohacking communities in the context of GH optimization and recovery, though its pronounced GHS-R desensitization with chronic use limits practical cycle duration.

Ranges sourced from published clinical trial data, pharmacokinetic literature, and community forums. Not dosing guidance.

A synthetic hexapeptide (D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2) that acts as a ghrelin/growth hormone secretagogue receptor (GHS-R1a) agonist. GHRP-2, also known by its INN pralmorelin, was the first growth hormone secretagogue introduced clinically and is approved in Japan as a diagnostic agent for growth hormone deficiency assessment. It has been studied in clinical trials for its effects on GH secretion in healthy adults and in children with short stature. In community biohacking contexts, it is discussed for its observed GH-stimulating properties with moderate appetite stimulation relative to GHRP-6. GHRP-2 is not approved for therapeutic use in the United States or Canada.

Ranges sourced from published clinical trial protocols, FDA 503B evaluation reports, and community forums. Not dosing guidance.

A synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) and met-enkephalin analogue that stimulates growth hormone release via the ghrelin/GHS-R1a receptor. GHRP-6 was the first growth hormone releasing hexapeptide to be extensively studied in humans and is one of the most widely referenced GHRPs in the scientific literature. It has been studied in clinical settings for GH secretion in adults and children, as well as in animal models for cytoprotective and cardioprotective effects. GHRP-6 is discussed frequently in community forums in the context of GH optimization and appetite stimulation, as it produces notably stronger hunger responses than GHRP-2 or ipamorelin. It is not approved for therapeutic use in the United States or Canada.

Ranges sourced from published clinical trial protocols, preclinical literature, and community forums. Not dosing guidance.

A synthetic tetrasubstituted analogue of growth hormone-releasing hormone (GHRH) 1-29 with a Drug Affinity Complex (DAC) that enables covalent binding to endogenous serum albumin after injection, dramatically extending its plasma half-life to approximately 6-8 days. Developed by ConjuChem Biotechnologies, CJC-1295 DAC incorporates amino acid substitutions at positions 2, 8, 15, and 27 plus a C-terminal Lys30 linked to a maleimidopropionyl group (the DAC moiety). This compound is distinct from CJC-1295 without DAC (also known as Modified GRF 1-29, slug: cjc-1295), which lacks the albumin-binding DAC component and has a much shorter half-life of approximately 30 minutes. CJC-1295 DAC reached Phase II clinical trials in humans for lipodystrophy and GH deficiency before being discontinued. It is not approved for therapeutic use in any jurisdiction.

Ranges sourced from Phase I/II clinical trial data, published preclinical literature, and community forums. Not dosing guidance.